GenVivo was founded on the idea that we can effectively treat cancer patients with the latest gene delivery technologies. We are committed to enhancing the overall patient treatment experience. We deliver innovative drugs to empower the patient’s own immune system to mount a targeted attack against cancer. These therapies are off-the-shelf and come without the cost and time delays associated with personalized cancer vaccines. We are dedicated to providing accessible and efficient solutions that redefine the landscape of cancer treatment. GenVivo is a fully-integrated. clinical stage company with in-house cGMP manufacturing for clinical drug product. Our lead candidate, GEN2, is in Phase I trials.